文献速递慢阻肺

茚达特罗/格隆溴铵与单药LAMA在未使用长效支气管扩张剂的COPD患者中的汇总分析

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
PubMed 文献 · Respirology · 2019-07-24

该汇总分析纳入ARISE、SHINE和SPARK三项试验中未使用长效支气管扩张剂的COPD患者998例,比较IND/GLY 110/50 μg每日一次与开放标签噻托溴铵18 μg每日一次或格隆溴铵50 μg每日一次的疗效。治疗24/26周后,IND/GLY在谷FEV1、症状评分、呼吸困难指数、生活质量和急救药物使用方面均优于单药LAMA。

要点

  • 在LABD初治COPD患者中,IND/GLY较噻托溴铵或格隆溴铵更改善谷FEV1。
  • IND/GLY在症状、呼吸困难、生活质量和急救药物使用方面亦优于单药LAMA。
  • IND/GLY组达到FEV1、TDI和SGRQ最小临床重要差异的患者比例更高。

核心结论

  • 对于未使用长效支气管扩张剂的COPD患者,IND/GLY 110/50 μg每日一次在肺功能、日常症状、呼吸困难、健康相关生活质量和急救药物使用方面均优于单药LAMA。

研究设计与样本

  • ARISE、SHINE和SPARK三项试验的汇总分析,纳入未使用长效支气管扩张剂的COPD患者998例(IND/GLY组353例,开放标签噻托溴铵组328例,格隆溴铵组317例),评估24/26周疗效。

主要发现

  • IND/GLY 110/50 μg每日一次较开放标签噻托溴铵18 μg每日一次谷FEV1最小二乘均值治疗差异为0.086 L,较格隆溴铵50 μg每日一次为0.080 L。
  • IND/GLY在电子日记症状评分、TDI焦点评分、SGRQ总分和急救药物使用方面的改善均大于开放标签噻托溴铵和格隆溴铵。
  • IND/GLY组达到谷FEV1、TDI和SGRQ最小临床重要差异的患者比例高于开放标签噻托溴铵和格隆溴铵组。

临床怎么用

  • 对于未使用长效支气管扩张剂的COPD患者,可考虑起始使用IND/GLY 110/50 μg每日一次以改善肺功能和相关临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (q.d.) has demonstrated greater improvements in lung function, patient-reported outcomes and lower exacerbation rates versus mono long-acting muscarinic antagonists (LAMA) in chronic obstructive pulmonary disease (COPD) patients. However, data are limited on initial treatment with IND/GLY 110/50 μg q.d. versus mono LAMA in COPD patients, not previously on maintenance treatment with long-acting bronchodilators (LABD). METHODS: A pooled analysis of ARISE, SHINE and SPARK trials was conducted to evaluate the efficacy of IND/GLY 110/50 μg q.d. versus open-label (OL) tiotropium (TIO) 18 μg q.d. and GLY 50 μg q.d. in COPD patients, not on maintenance treatment with LABD at study entry (LABD-naïve). Efficacy was assessed after 24/26 weeks of treatment. RESULTS: In total, 998 LABD-naïve patients were included (IND/GLY: 353; OL TIO: 328; GLY: 317). Patients treated with IND/GLY 110/50 μg q.d. experienced greater improvements in trough forced expiratory volume in 1 s (FEV1 ) versus OL TIO 18 μg q.d. (least squares mean treatment difference (Δ): 0.086 L) and GLY 50 μg q.d. (Δ: 0.080 L) after 24/26 weeks. Improvements in electronic diary (eDiary) symptom scores, transition dyspnoea index (TDI) focal score, St George's Respiratory Questionnaire (SGRQ) total score and rescue medication use were also greater with IND/GLY versus OL TIO and GLY. Greater proportion of patients achieved minimal clinically important difference in trough FEV1 , TDI and SGRQ with IND/GLY versus OL TIO and GLY. CONCLUSION: LABD-naïve patients treated with IND/GLY 110/50 μg q.d. achieved improvements in lung function, daily symptoms, dyspnoea, health-related quality of life and rescue medication use versus those who received single LAMA.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Muro S, Yoshisue H, Kostikas K, et al. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis. Respirology. 2019. PMID: 31339215. doi:10.1111/resp.13651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。